|
iX Biopharma, whose stock has shot up 157% year-to-date (to 35 cents), has announced a strategic internal restructuring to consolidate its consumer-facing assets under a new subsidiary, Ligo Pharma. |
| 10 takeaways from iX Biopharma's announcement |
- Creating a dedicated US subsidiary: iX is reorganising to aggressively target the US consumer health market by forming a new, 100%-owned subsidiary called Ligo Pharma.
- Consolidating consumer assets: Ligo will house iX's consumer operations from Australia and Hong Kong, roughly 40 of its "WaferiX" drug formulations, and a new direct-to-consumer telehealth platform that is currently being built.
iX is leveraging on strong demand for peptides (small chains of amino acids used in medicines or wellness products for things like anti-aging, recovery, or hormone support).
When it comes to the peptides, the sublingual delivery technology has a strong advantage as it is preferred by consumers over injections or needles. - Protecting core pharma assets: Major pharmaceutical assets of iX, including the Wafermine pain drug and the new US Department of Defence contracts, are completely unaffected by this move and will stay with the parent company, iX.
- No immediate financial impact: For investors, this internal reshuffle is purely strategic and will not negatively impact the company's overall net assets or earnings per share for the current financial year.
| Peptide opportunities |
| "Peptides are one of the most significant emerging opportunities in US compounding today. In early 2026, the US authorities removed 12 peptides from the restricted compounding list and scheduled a formal advisory committee review for July 2026 to consider their availability through licensed compounding pharmacies. A favourable outcome could open a substantial new addressable market through the compounding pathway." -- iX Biopharma |
- Bypassing lengthy FDA delays: A major financial benefit of this setup is that iX can immediately sell its products to wealthy, health-conscious US consumers using special US pharmacy rules, completely bypassing the wait for standard FDA approvals.
- Targeting higher telehealth valuations: Instead of just mixing and shipping drugs, Ligo aims to be a full direct-to-consumer telehealth business, a sector that typically commands much higher valuations from investors than traditional pharmaceutical distributors.
- A unique "needle-free" selling point: While competitors mostly sell generic injections, Ligo will stand out by offering iX's patented "melt-under-the-tongue" (sublingual) wafers, providing an innovative and painless alternative for patients.
- First-mover advantage in "peptides": The US is currently reviewing regulations that may open up a massive market for a popular class of drugs called peptides by July 2026; having local operations ready gives iX a head start to deliver these without needles as soon as the market opens.
"iX has the technology capable of delivering peptides sublingually, without injection, and several peptides in iX's own pipeline are among those under active regulatory review. This is a meaningful first-mover advantage in a market that is not yet open," says iX. - Solving supply chain headaches: Manufacturing the products directly in the US is a necessary business move, as supplying them from Australia would be uncompetitive due to tariffs, strict drug ingredient limits, and potential shipping delays.
|
→ See also:iX Biopharma: Broker Issues Rare 5X Target. How Did It Arrive At That?
